The study’s failure may have been due to a combination of an insensitive trial design, a blocking effect of standard drugs, too high a dose of ethyl EPA in the active group, and a dietary increase in EPA in the placebo group. Further studies are required, particularly with lower doses of ethyl EPA in otherwise untreated patients, before any firm conclusions can be drawn. Such studies are important because ethyl EPA is so well tolerated. Of 43 patients receiving ethyl EPA, only six (14%) dropped out during the 16-week study—none because of side effects. In the dose-ranging study of depression (8), only 12% of the patients taking any ethyl EPA dropped out, while in the dose-ranging schizophrenia study (6), only 11% dropped out. These dropout rates are much lower than those seen with standard antidepressant or antischizophrenia drugs. Even a modest beneficial effect would be valuable if produced by such a safe drug.